Literature DB >> 25976643

Patterns of ranibizumab and aflibercept treatment of central retinal vein occlusion in routine clinical practice in the U.S.A.

D Călugăru1, M Călugăru1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25976643      PMCID： PMC4541350          DOI： 10.1038/eye.2015.68

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN： 0950-222X            Impact factor:   3.775


× No keyword cloud information.
  5 in total

1.  Intravitreal aflibercept for macular edema secondary to central retinal vein occlusion: 18-month results of the phase 3 GALILEO study.

Authors:  Yuichiro Ogura; Johann Roider; Jean-François Korobelnik; Frank G Holz; Christian Simader; Ursula Schmidt-Erfurth; Robert Vitti; Alyson J Berliner; Florian Hiemeyer; Brigitte Stemper; Oliver Zeitz; Rupert Sandbrink
Journal:  Am J Ophthalmol       Date:  2014-07-25       Impact factor: 5.258

2.  Long-term outcomes in patients with retinal vein occlusion treated with ranibizumab: the RETAIN study.

Authors:  Peter A Campochiaro; Raafay Sophie; Joel Pearlman; David M Brown; David S Boyer; Jeffrey S Heier; Dennis M Marcus; Leonard Feiner; Arun Patel
Journal:  Ophthalmology       Date:  2013-10-07       Impact factor: 12.079

3.  Intravitreal bevacizumab in acute central/hemicentral retinal vein occlusions: three-year results of a prospective clinical study.

Authors:  Dan Călugăru; Mihai Călugăru
Journal:  J Ocul Pharmacol Ther       Date:  2014-10-14       Impact factor: 2.671

4.  Intravitreal aflibercept injection for macular edema due to central retinal vein occlusion: two-year results from the COPERNICUS study.

Authors:  Jeffrey S Heier; W Lloyd Clark; David S Boyer; David M Brown; Robert Vitti; Alyson J Berliner; Husain Kazmi; Yu Ma; Brigitte Stemper; Oliver Zeitz; Rupert Sandbrink; Julia A Haller
Journal:  Ophthalmology       Date:  2014-03-27       Impact factor: 12.079

5.  Patterns of ranibizumab and aflibercept treatment of central retinal vein occlusion in routine clinical practice in the USA.

Authors:  A J Lotery; S Regnier
Journal:  Eye (Lond)       Date:  2015-01-09       Impact factor: 3.775
  5 in total
  3 in total

1.  Response to 'Patterns of ranibizumab and aflibercept treatment of central retinal vein occlusion in routine clinical practice in the U.S.A.'.

Authors:  A Lotery; S Regnier
Journal:  Eye (Lond)       Date:  2015-05-15       Impact factor: 3.775

2.  Response to Comment on: Treatment patterns of ranibizumab intravitreal injection and dexamethasone intravitreal implant for retinal vein occlusion in the USA.

Authors:  S Nghiem-Buffet; S Baillif; S Regnier; A Skelly; N Yu; A Sodi
Journal:  Eye (Lond)       Date:  2017-02-24       Impact factor: 3.775

Review 3.  Bevacizumab in the treatment of acute central/hemicentral retinal vein occlusions.

Authors:  Dan Călugăru; Mihai Călugăru; Ștefan Țălu
Journal:  Rom J Ophthalmol       Date:  2016 Jul-Sep
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.